Ashwagandha (Withania somnifera) and Shunthi (Zingiber officinale) in mild and moderate COVID-19: An open-label randomized controlled exploratory trial
Singh H, Yadav B, Rai AK, Srivastava S, Saiprasad A, Jameela S, Singhal R, Muralidharan S, Mohan R, Chaudhary S, Rana R, Khanduri S, Sharma BS, Chandrasekhararao B, Srikanth N, Dhiman KS
Complementary therapies in medicine · 8 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2023-07-22 · Complement Ther Med · vol. 76 · pág. 102966
- Editorial
- Elsevier BV
- Citado
- 17 citas · más que el 95% de estudios similares · 5.3× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 53 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY-NC-ND
- Áreas de investigación
- Phytochemicals and Medicinal Plants · Andrographolide Research and Applications · Piperaceae Chemical and Biological Studies
- Palabras clave
- Withania somnifera, Medicine, Zingiber officinale, Adverse effect, Randomized controlled trial, Coronavirus disease 2019 (COVID-19), Traditional medicine, Internal medicine, Clinical trial, Alternative medicine, Disease, Pathology
- MeSH
- humans, withania, immunoglobulin g, plant extracts, treatment outcome, pandemics, biomarkers, covid-19, zingiber officinale
16 autores
- Harbans Singh🇮🇳Central Council for Research in Ayurvedic Science
- Babita Yadav🇮🇳Central Council for Research in Ayurvedic Science
- Amit K. Rai🇮🇳 · autor de correspondenciaCentral Council for Research in Ayurvedic Science
- Sumit Kumar Srivastava🇮🇳Government Ayurvedic College and Hospital
- A.J.V. Saiprasad
- Sophia Jameela🇮🇳Central Council for Research in Ayurvedic Science
- Richa Singhal🇮🇳Central Council for Research in Ayurvedic Science
- Sanuj Muralidharan🇮🇳Government Ayurvedic College and Hospital
- Rijin Mohan🇮🇳Government Ayurvedic College and Hospital
- Shikha Chaudhary🇮🇳Government Ayurvedic College and Hospital
- Rakesh Kumar Rana🇮🇳Central Council for Research in Ayurvedic Science
- Shruti Khanduri🇮🇳Central Council for Research in Ayurvedic Science
- BS Sharma🇮🇳Central Council for Research in Ayurvedic Science
- Bhogavalli Chandrasekhararao🇮🇳Central Council for Research in Ayurvedic Science
- Narayanam Srikanth🇮🇳Central Council for Research in Ayurvedic Science
- Kartar Singh Dhiman🇮🇳Central Council for Research in Ayurvedic Science
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Ayurveda interventions have been used for prophylaxis and care during the COVID-19 pandemic in India and have shown promising results in promoting early clinical recovery from COVID-19.
Objective
To assess the efficacy and safety of Ashwagandha [Withania somnifera (L.) Dunal] tablet and Shunthi (Zingiber officinale Roscoe) capsule in mild and moderate COVID-19 compared to conventional standard care.
Methods
A randomized controlled exploratory trial was conducted at a designated COVID-19 care center in India with 60 participants having mild or moderate COVID-19. Ashwagandha, two tablets (250 mg each), and Shunthi, two capsules (500 mg each) twice daily for 15 days, were given orally to the participants in the Ayurveda group (AG) and the control group (CG) received conventional standard care. The outcome measures included clinical recovery rate, the proportion of participants with negative RT-PCR assay for COVID-19 on day 7 and day 15, mean time to attain clinical recovery, change in pro-inflammatory markers, serum IgG for COVID-19, HRCT chest findings, disease progression and incidence of adverse events (AE).
Results
A total of 60 participants were enrolled, and the data of 48 participants (AG = 25 and CG = 23) were considered for the statistical analysis. The mean time for clinical recovery was reduced by almost 50 % in the AG (6.9 days) compared to CG (13.0 days) (p < 0.001). The proportion of participants who attained viral clearance in AG was 76.0 % compared to 60.8 % in the CG (RR= 1.24, 95 % CI: 0.841, 1.851, p-value = 0.270). Changes in the pro-inflammatory markers, serum IgG for COVID-19, and HRCT chest findings were comparable in both groups, and no AE or disease progression was reported.
Conclusions
The Ayurveda interventions, Ashwagandha and Shunthi, can effectively reduce the duration of clinical recovery and improve time for viral clearance in mild and moderate COVID-19. These interventions were observed to be safe and well-tolerated during the duration of the trial.
Trial registration
Clinical Trial Registry of India - CTRI/2020/08/027224.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC-ND).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.